$CORT Corcept Therapeutics recently presented new, positive data from the Phase 3 ROSELLA trial at the ESMO 2025 Annual Meeting showing that relacorilant plus nab-paclitaxel improves progression-free survival in patients with platinum-resistant ovarian cancer, including those previously treated with PARP inhibitors.
The results suggest that relacorilant may offer a clinically meaningful benefit for a particularly high-risk patient population where chemotherapy resistance is a major challenge.
We will explore how the compelling Phase 3 results in oncology could impact Corcept Therapeutics' prospects for pipeline diversification and revenue growth.
The results suggest that relacorilant may offer a clinically meaningful benefit for a particularly high-risk patient population where chemotherapy resistance is a major challenge.
We will explore how the compelling Phase 3 results in oncology could impact Corcept Therapeutics' prospects for pipeline diversification and revenue growth.
••
@asset_sage_389 I remain invested
••